Abstract
Adoptive immunotherapy of cancer using T cells expressing chimeric antigen receptors (CARs) is now an approved treatment for non-Hodgkin lymphoma (NHL) and B cell acute lymphoblastic leukemia (B-ALL), inducing high response rates in patients. The infusion products are generated by using retro- or lentiviral transduction to induce CAR expression in T cells followed by an in vitro expansion protocol. However, use of viral vectors is cumbersome and is associated with increased costs due to the required high titers, replication-competent retrovirus (RCR) detection and production/use in a biosafety level 2 culture rooms, and additional quality control tests. Nonviral methods, like the Sleeping Beauty transposon system, can stably integrate in the genome of target cells and can be delivered using straightforward methods like electroporation. This chapter describes a protocol for T cell genetic modification using Sleeping Beauty transposon system and electroporation with the Lonza Nucleofector II device for the stable expression of CAR molecules in T lymphocytes.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Maude SL, Laetsch TW, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439–448
Park JH, Riviére I, Gonen M et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449–459
Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531–2544
June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Engl J Med 379(1):64–73
Levine BL, Miskin J, Wonnacott K et al (2017) Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev 4:92–101
Wang X, Rivière I (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 3:16015
Ivics Z, Hackett PB, Plasterk RH et al (1997) Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91(4):501–510
Mátés L, Chuah MK, Belay E et al (2009) Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 41(6):753–761
Chicaybam L, Sodre AL, Curzio BA et al (2013) An efficient low cost method for gene transfer to T lymphocytes. PLoS One 8(3):e60298
Peng PD, Cohen CJ, Yang S et al (2009) Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther 16(8):1042–1049
Huang X, Guo H, Tammana S et al (2010) Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and PiggyBac transposons in human primary T cells. Mol Ther 18(10):1803–1813
Moldt B, Miskey C, Staunstrup NH et al (2011) Comparative genomic integration profiling of Sleeping Beauty transposons mobilized with high efficacy from integrase-defective lentiviral vectors in primary human cells. Mol Ther J Am Soc Gene Ther 19(8):1499–1510
Field AC, Vink C, Gabriel R et al (2013) comparison of lentiviral and Sleeping Beauty mediated αβ T cell receptor gene transfer. PLoS One 8(6):e68201
Kebriaei P, Singh H, Huls MH et al (2016) Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363–3376
Neumann E, Schaefer-Ridder M, Wang Y et al (1982) Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1(7):841–845
Tsong TY (1991) Electroporation of cell membranes. Biophys J 60(2):297–306
Imai C, Mihara K, Andreansky M et al (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18(4):676–684
Siddappa NB, Avinash A, Venkatramanan M et al (2007) Regeneration of commercial nucleic acid extraction columns without the risk of carryover contamination. BioTechniques 42(2):186
Ghassemi S, Nunez-Cruz S, O'Connor RS et al (2018) Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol Res 6(9):1100–1109
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Chicaybam, L., Abdo, L., Bonamino, M.H. (2020). Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System. In: Swiech, K., Malmegrim, K., Picanço-Castro, V. (eds) Chimeric Antigen Receptor T Cells. Methods in Molecular Biology, vol 2086. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0146-4_9
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0146-4_9
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0145-7
Online ISBN: 978-1-0716-0146-4
eBook Packages: Springer Protocols